Shan Ahmed Khan

Shan Ahmed Khan is a senior markets reporter at TS2.tech, specializing in stocks, technology and macroeconomic trends. A graduate of the Lahore University of Management Sciences (LUMS), he previously worked in investment research and market analysis. His coverage helps readers understand the key developments influencing global financial markets and emerging industries.

HSBC share price set for Monday spotlight as profit-target talk swirls ahead of results

HSBC share price set for Monday spotlight as profit-target talk swirls ahead of results

HSBC Holdings’ shares are likely to grab early attention in London Monday after insiders indicated the bank plans to boost its key profitability target in next month’s annual results. The bank is tipped to raise its return-on-tangible-equity forecast beyond the current “mid teens or better” range. Some analysts suggest the upgrade could be around two percentage points. HSBC declined to comment. Peter Rothwell, KPMG UK’s head of banking, noted lenders are seeing “earnings resilience lasting longer than initially expected,” supported by higher rates, credit quality, and cost control.
26 January 2026
GSK stock in focus as EU expands Arexvy RSV vaccine approval to all adults 18+

GSK stock in focus as EU expands Arexvy RSV vaccine approval to all adults 18+

GSK announced that the European Commission has greenlit its RSV vaccine Arexvy for adults 18 and older, expanding eligibility beyond those 60-plus and high-risk individuals aged 50 to 59. “This approval helps protect all adults aged 18 and older in Europe against RSV,” said Sanjay Gurunathan, GSK’s head of Vaccines and Infectious Diseases R&D. The approval applies across EU member states and countries in the European Economic Area. GSK pointed to an average of 158,000 RSV-related adult hospitalisations annually within the EU.
1 173 174 175 176 177 609
AI PORTFOLIO

Top Stock Picks

Today’s highest-ranked model selections.

#1 STRONG BUY

Xylem

NYSE: XYL 94 / 100
#2 STRONG BUY

AerCap

NYSE: AER 92 / 100
#3 BUY ON WEAKNESS

Visa

NYSE: V 90 / 100
#4 BUY

Chevron

NYSE: CVX 86 / 100
#5 ACCUMULATE

UPS

NYSE: UPS 84 / 100
View full portfolio
Editorial model selection. Not personalised advice.